Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

mpany has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its recent acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer's disease. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.  

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release contains forward-looking statements regarding Sangamo's current expectations.  These forward looking statements include, without limitation, references to anticipated yearend cash and investment balance, operating expenses and revenue, the research and development of ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform, achievement of research milestones and objectives, strategic partnership and commer
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
2. Sangamo BioSciences Proposes Public Offering Of Common Stock
3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Will Focus on Identifying New Biotech Traits to Improve Farmer ... ... DuPont and Beijing Weiming,Kaituo Agriculture Biotechnology Co., Ltd. (BWK) today ... genes for high,value agronomic traits such as stress tolerance and efficient ...
... 3 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ... of cancer and,hepatitis C virus (HCV) infection, today announced ... quarter of fiscal year 2008 on December,10, 2007 at ... and webcast to,discuss the results at 11:30 a.m. EST ...
... force microscope, the tiny structures look like fragments of ... molecules that are linked together by means of a ... threading these nanopearls in the latest issue of the ... made of 60 carbon atoms whose linkages resemble the ...
Cached Biology Technology:DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 2DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts 3Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results 2
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... utilizing black platinum and carbon nanotubes developed at Purdue ... how the plant hormone auxin regulates root growth and ... agricultural and biological engineering and biomedical engineering, created a ... a plant,s root surface in real time without damaging ...
... effective cancer treatment, also brings debilitating side effects such as ... Now, a new way to deliver this life-saving therapy ... the disease has been invented by Dr. Dan Peer ... and the Center for Nano Science and Nano Technology together ...
... program BioEYES has now been adopted by the University ... down-under partnership program debuts this August. BioEYES is designed ... science in elementary, middle, and high school students. Over ... zebrafish, Danio rerio, grow from a single-celled zygote to ...
Cached Biology News:Sensor important to understanding root, seedling development 2A cluster bomb for cancer care 2Educational pioneer BioEYES goes Down Under 2
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: